Institutional conviction in Indian pharmaceuticals is narrowing toward operational resilience.
Shanika Capital Advisors has identified Zydus Lifesciences and Granules India as standout winners in the domestic drug manufacturing landscape, positioning both companies to capture outsized market share over a three-to-five-year horizon. Managing Partner Anmol Ganjoo flagged the two drugmakers as distinct plays across capitalisation tiers, separating frontline stability from high-upside mid-cap value.
Zydus Lifesciences commands the top tier in the large-cap basket. But the sharper tactical debate centers on Granules India. The mid-cap drugmaker has weathered acute regulatory pushback following a US Food and Drug Administration warning letter issued to its flagship Gagillapur manufacturing plant in Telangana. The market grew cautious. Ganjoo, however, dismissed the broader pessimism, pointing straight to operating data.
Gagillapur continues to run at approximately 75% capacity utilisation despite the regulatory censure. The plant is not idling. At the same time, Granules is de-risking its pipeline by shifting incremental regulatory dossiers elsewhere. High-value product filings are now rolling out from its Virginia site in the United States and its Genome Valley unit in Hyderabad.
The geographic pivot shields future commercial launches from single-site regulatory bottlenecks. That insulation allows Granules India to preserve cash flows while regulatory compliance discussions at Gagillapur proceed. By pairing large-cap balance sheet strength at Zydus with incremental pipeline execution at Granules, Shanika Capital is laying down a multi-year blueprint predicated on manufacturing depth rather than short-term market noise.